hospitalised patient – Page 4 – Communicable Diseases Research

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

입원한 COVID-19 폐렴 환자에 대한 렌질루맙(LIVE-AIR): 3상, 무작위, 위약 대조 시험

Clinical Trial

Published on 2022-03-012022-09-12
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단,

Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients

Observational Study

Published on 2022-03-012022-10-04
Journal: European Journal of Hospital Pharmacy [Category] SARS, 임상,

[키워드] activities Admission Adverse adverse event age Anti-inflammatory Baricitinib C-reactive protein clinical clinical benefit Clinical improvement Corticosteroid COVID-19 Critical Critical care Cytokine storm syndrome education Effectiveness event Evidence-based medicine ferritin hospital discharge hospitalised hospitalised patient immunomodulator improvement inhibitor interleukin-6 IQR laboratory parameter limitation Lymphocytes men Patient Pharmacy Platelet poor prognosis pulmonary medicine Randomised trial reported Retrospective study risk factor severe COVID-19 survival Time to recovery treated Treatment viral endocytosis Virology
[DOI] 10.1136/ejhpharm-2021-002741 PMC 바로가기 [Article Type] Observational Study

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

COVID-19 입원 환자의 초기 중증도 바이오마커로서의 비인두 미생물총

Article

Published on 2022-03-012022-09-11
Journal: The Journal of Infection [Category] MERS, SARS, 바이오마커,

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

입원한 COVID-19 환자의 표준 치료와 비교한 나밀루맙 또는 인플릭시맙(CATALYST): 무작위, 다기관, 다군, 다단계, 공개 라벨, 적응형, 2상, 개념 증명 시험

Clinical Trial

Published on 2022-03-012022-09-12
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단,

[키워드] 95% CI adaptive adverse event analysed assigned Bayesian C-reactive protein (CRP Care colony stimulating factor Complete Concentration COVID-19 CRP Efficacy enrolled Evidence FIVE greater hospital hospitalised patient Inflammation inhibitor intensive care Interaction Intervention intravenous dose investigator ISRCTN Medical Research Council multi-arm multicentre Necrosis nine occurred Open-label outcome parallel-group participant Patient Phase 3 trials Pneumonia point estimate primary endpoint Primary outcome Probability randomised Randomly recruited reducing reduction in Registered screened Standard of care stratified treatment allocation Trial usual care usual care alone usual care group with COVID-19
[DOI] 10.1016/S2213-2600(21)00460-4 PMC 바로가기 [Article Type] Clinical Trial

Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study

Observational Study

Published on 2022-02-282022-10-04
Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상,

[키워드] 95% CI adverse outcomes age all-cause mortality Antiviral change changed Characteristics Clinical diagnosis Clinical outcome clinical outcomes Cohort cohort study cohorts COVID-19 COVID-19 patient cumulative death Decline declined Dexamethasone Electronic health records elevated Epidemiology flat hospital hospitalised hospitalised patient In-hospital In-hospital death incidence incident Laboratory Observational cohort study outcome Patient positive proportion public health remained risk secondary outcome subset the disease the median Treatment trend USA use of hydroxychloroquine with COVID-19 women
[DOI] 10.1136/bmjopen-2021-055137 PMC 바로가기 [Article Type] Observational Study

Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital

동적 시간 왜곡 분석을 사용한 바이오마커 식별: 영국 3차 병원의 COVID-19 환자에 대한 종단 코호트 연구

Article

Published on 2022-02-152022-09-11
Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 바이오마커,

[키워드] Admission Analysis association biochemical biochemical parameter blood tests board C reactive protein change clinical benefit clinical feature clinical response clinical utility COVID-19 CRP D-dimer decrease decreases described determined by discharge discharged disease Disease progression East England Ethical approval ferritin healthcare heterogeneous high mortality highest hospital hospitalised patient Hospitalised patients HRA increase Increases information Informed consent Laboratory Lactate lactate dehydrogenase limit longitudinal change longitudinal changes longitudinal cohort study lowest lymphocyte Lymphocyte count majority Mortality Most patients neutrophil neutrophil counts outcome pandemic Patient patients patients treated patients with COVID-19 Platelet platelet counts prognostic prognostic variable REC respiratory respiratory infections respiratory medicine (see thoracic medicine) retrospective review risk routine blood test routine blood tests SARS-CoV-2 South Specific symptom onset Thoracic Treatment response urea Variation variations waiver was obtained white cell with COVID-19
[DOI] 10.1136/bmjopen-2021-050331 PMC 바로가기 [Article Type] Article

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Randomized Controlled Trial

Published on 2022-02-102022-10-04
Journal: The European Respiratory Journal [Category] COVID19(2023년), SARS, 임상,

[키워드] 1:1 28-day mortality 95% CI age Antibody titre assigned baseline Clinical improvement clinical trial convalescent plasma coronavirus disease COVID-19 Critically ill days alive Effect enrolment group groups hospitalised hospitalised patient interquartile range invasive investigator-initiated IQR Laboratory male marker median no significant difference Open-label Parallel Arm Patient patients plasma Primary outcome proportion randomisation randomised Randomly Respiratory Support Secondary outcomes Standard of care subgroups symptom onset the median therapy Trial ventilatory support with COVID-19
[DOI] 10.1183/13993003.01471-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial

Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

Research

Published on 2022-02-102022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] Analysis applied approach article articles Asia Brazil Care Combination conducted country Coverage COVID-19 COVID-19 infection COVID-19 vaccinations Critical effective eligible English estimate Europe Evidence feasibility HAI healthcare healthcare worker high risk hospital Hospital acquired Hospital acquired infections hospitalised patient hospitalized patients identify implementation increased risk Infection infections Intervention literature North America not differ operative Operative surgery Patient patients peer-reviewed presenting prevented proportion protocols Psychiatric Public healthcare Quality ranged reduce reported Result selected supplementary material vaccination Vaccine Web of Science
[DOI] 10.1186/s12879-022-07128-5 PMC 바로가기 [Article Type] Research

Clinical and laboratory characteristics of patients hospitalised with COVID-19: clinical outcomes in Abu Dhabi, United Arab Emirates

Research Article

Published on 2022-02-082022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] Abu acute respiratory syndrome affected age analysed Analysis Anti-viral therapy average C-reactive protein China Chronic kidney disease clinical Clinical features Clinical outcome co-morbidities co-morbidity Cohort collected Combination coronavirus coronavirus disease COVID-19 creatinine Diabetes Mellitus diagnosis of SARS-CoV-2 disease disease severity Electronic health record facility ferritin groups health information highest Hospital stay hospitalised hospitalised patient hypertension in-hospital mortality rate Infection intensive care interleukin-6 International Italy Laboratory laboratory characteristics laboratory feature Laboratory test laboratory-confirmed lactate dehydrogenase less male Mild moderate disease morbidity and mortality Mortality mortality rate neutrophil count Older outcome outcomes Patient patient data patients PCR reported required Result Retrospective analysis SARS‐CoV‐2 service severe group severity significant difference suggested Treatment United Arab Emirate Volume with COVID-19
[DOI] 10.1186/s12879-022-07059-1 PMC 바로가기 [Article Type] Research Article

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

입원한 COVID-19 환자를 위한 과면역 면역글로불린(ITAC): 이중 맹검, 위약 대조, 3상, 무작위 시험

Clinical Trial

Published on 2022-02-052022-09-11
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, 치료제,

[키워드] 1:1 95% CI addition adjusted Administered adverse events Analysis Anti-spike antibody assigned baseline carried clinical care clinical trials Complication COVID-19 death donors double-blind duration of symptoms Efficacy Efficacy and safety eligibility criteria end-organ Endpoint enrolled Evidence evidence of Factors finding greater Group allocation heterogeneity hospitalised hospitalised patient Hospitalised patients hyperimmune Immunoglobulin Immunotherapy Infection infusion Interaction International Intravenous immunoglobulin investigators mass mITT mITT analysis modified intention-to-treat Neutralising Antibodies neutralising antibody Organ failure outbreak outcome participant Passive Patient Phase 3 Placebo placebo group placebo-controlled placebo-controlled trial positive Primary outcome randomisation randomised randomised clinical trial Randomised trial Randomly ranged reaction receive Registered Remdesivir Research risk Saline SARS-CoV-2 serious infections significantly Standard of care stratified subgroup subgroups Symptom symptomatic therapy to define Treatment treatment of COVID-19 Trial trial participant trial participants Volume was measured were used with COVID-19
[DOI] 10.1016/S0140-6736(22)00101-5 PMC 바로가기 [Article Type] Clinical Trial